Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Clinical Immunology · ITCH Deficiency

Building Your Care Team for ITCH Deficiency

At a Glance

Children with ITCH deficiency benefit from coordinated care at an academic center experienced in primary immune regulatory disorders. A clinical immunologist can connect liver, gut, lung, endocrine, genetic, and transplant care and coordinate with local doctors.

Because ITCH deficiency is a multisystem disorder, your child’s care cannot be managed by a single doctor. It requires a symphony of specialists working in perfect coordination. Because this condition is so rare—with only about 15 cases known worldwide—it is highly recommended to consult with a major academic medical center with a dedicated program for Primary Immune Regulatory Disorders (PIRD) [1][2].

Why a Specialized Center Matters

A general hospital or even a standard pediatric clinic may have excellent doctors, but they likely lack the specific infrastructure needed for a PIRD. Specialized centers offer several critical advantages:

  • Unifying the Diagnosis: In a specialized center, the clinical immunologist and geneticist work together to connect seemingly unrelated symptoms—like liver inflammation and lung disease—back to the ITCH gene defect [3][4].
  • Expertise in Immune “Brakes”: Doctors at these centers understand the specific pathways (like NF-κB or IL-17) that are overactive in ITCH deficiency and can select targeted off-label medications that a generalist might not be familiar with [5][6].
  • Transplant Precision: If your child needs a hematopoietic stem cell transplant (HSCT), the team must be experienced in transplanting children with immune dysregulation, not just cancer. This involves carefully controlling inflammation before the transplant to improve the chances of success [7][8].

The Multidisciplinary Team

Your child’s “Core Team” should ideally be able to communicate seamlessly. This team often includes:

  • Clinical Immunologist: The “quarterback” who manages the overall immune system and coordinates the other specialists [9].
  • Hepatologist (Liver Specialist): Monitors for autoimmune hepatitis and manages liver health [10].
  • Gastroenterologist (GI Specialist): Manages very-early-onset inflammatory bowel disease (VEO-IBD) and nutrition [1].
  • Pulmonologist (Lung Specialist): Screens for and treats chronic lung changes like bronchiectasis [11].
  • Endocrinologist: Monitors for type 1 diabetes and thyroid issues [1].
  • HSCT Specialist: Evaluates the timing and risks of a stem cell transplant [7].
  • Genetic Counselor: Helps your family understand the autosomal recessive nature of the disease and provides guidance for future family planning [3].
  • Supportive Care: Infectious disease experts, nutritionists, pharmacists, social workers, and psychologists as clinically indicated.

Vetting a Medical Center

When you meet with a potential care team, do not be afraid to ask direct questions. A center prepared to handle a condition as complex as ITCH deficiency will welcome your engagement. Consider asking:

  1. “Does this center have a specialized PIRD or immune dysregulation clinic?” You want a team that sees these immune regulatory problems regularly, even if they haven’t seen ITCH deficiency specifically [12].
  2. “What is your experience with HSCT for non-malignant (non-cancer) diseases?” The conditioning and recovery process for a child with an overactive immune system is very different from that of a child with leukemia [13].
  3. “How does the team communicate across specialties?” Ask if they hold “multidisciplinary immune-dysregulation case conferences” where all your child’s doctors sit in one room to discuss the plan [9].
  4. “What are your long-term follow-up protocols?” Children who survive PIRDs after a transplant need lifelong monitoring for immune health and organ function [14][15].

A Shared-Care Model and the Parent-Advocate

Often, a shared-care model can be established where the expert center designs the overarching plan, and your local pediatrician or specialists execute routine care and urgent sick visits. In the world of rare disease, you are the most consistent member of the care team. While the specialists provide the medical expertise, you provide the “real-world” data on how your child is feeling and growing. By building a team at a specialized center, you ensure that your child has access to the most current research, the safest transplant protocols, and a group of experts who are dedicated to managing this rare journey alongside you.

Common questions in this guide

What type of medical center should care for a child with ITCH deficiency?
A major academic medical center with a program for primary immune regulatory disorders or immune dysregulation is often best equipped for this rare condition. The center should be able to coordinate immunology, genetics, organ specialists, and transplant care while working with local doctors.
Which specialists should be involved in ITCH deficiency care?
A clinical immunologist commonly coordinates the team, which may include a geneticist, liver specialist, gastroenterologist, pulmonologist, endocrinologist, and stem cell transplant specialist. Infectious disease, nutrition, pharmacy, social work, and psychology support may also be needed.
How should I evaluate a transplant center for ITCH deficiency?
Ask how much experience the team has treating children with non-cancer immune disorders and how it controls inflammation before a stem cell transplant. Also ask about transplant risks, long-term follow-up, and communication among all specialists.
Does every child with ITCH deficiency need a stem cell transplant?
Not every child will need a hematopoietic stem cell transplant. A specialist team evaluates the child’s immune activity, organ involvement, overall health, and potential benefits and risks before recommending whether transplant should be considered.
How can a specialty center and our local doctors share my child’s care?
The specialty center can create the overall plan and advise on complex immune or transplant decisions, while local doctors provide routine visits and urgent care closer to home. Clear written plans, shared records, and a named coordinator help keep everyone aligned.
Why is long-term follow-up important after treatment for ITCH deficiency?
Children with ITCH deficiency may need ongoing monitoring of immune health and organ function, including after a transplant. Regular follow-up helps the team identify new inflammation, complications, or treatment needs early.

Get notified when new evidence is published on Syndromic multisystem autoimmune disease due to Itch deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Immune Dysregulation in Human ITCH Deficiency Successfully Treated with Hematopoietic Cell Transplantation.

    Patel T, Henrickson SE, Moser EK, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(7)):2885-2893.e3 doi:10.1016/j.jaip.2021.04.010.

    PMID: 33894394
  2. 2

    Case Report: Sustained immune and pulmonary recovery three years after hematopoietic stem cell transplantation for ITCH E3 ubiquitin ligase deficiency.

    Ashe B, Neal E, Kurland G, et al.

    Frontiers in immunology 2026; (17()):1805196 doi:10.3389/fimmu.2026.1805196.

    PMID: 42148098
  3. 3

    Immunodeficiency: Overview of primary immune regulatory disorders (PIRDs).

    Nelson CS, Baloh CH

    Allergy and asthma proceedings 2024; (45(5)):332-339 doi:10.2500/aap.2024.45.240070.

    PMID: 39294916
  4. 4

    Primary immune regulatory disorders: a growing universe of immune dysregulation.

    Chan AY, Torgerson TR

    Current opinion in allergy and clinical immunology 2020; (20(6)):582-590 doi:10.1097/ACI.0000000000000689.

    PMID: 32941318
  5. 5

    Itch inhibits IL-17-mediated colon inflammation and tumorigenesis by ROR-γt ubiquitination.

    Kathania M, Khare P, Zeng M, et al.

    Nature immunology 2016; (17(8)):997-1004 doi:10.1038/ni.3488.

    PMID: 27322655
  6. 6

    Phosphorylation of the E3 ubiquitin protein ligase ITCH diminishes binding to its cognate E2 ubiquitin ligase.

    Perez JM, Chen Y, Xiao TS, Abbott DW

    The Journal of biological chemistry 2018; (293(3)):1100-1105 doi:10.1074/jbc.RA117.000408.

    PMID: 29212706
  7. 7

    How I Treat: Transplantation for primary immune regulatory diseases and inflammatory disorders.

    Oved JH

    Journal of human immunity 2026; (2(6)) doi:10.70962/jhi.20250147.

    PMID: 42831798
  8. 8

    Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study.

    Tsilifis C, Speckmann C, Lum SH, et al.

    The Journal of allergy and clinical immunology 2024; (154(6)):1534-1544 doi:10.1016/j.jaci.2024.08.020.

    PMID: 39218359
  9. 9

    Multidisciplinary approach to early identification of inborn errors of immunity in patients with lymphoproliferation.

    Alsina L, Celis Passini V, Garrido Colino C, et al.

    Leukemia & lymphoma 2026; (67(11)):2192-2205 doi:10.1080/10428194.2026.2704265.

    PMID: 42518275
  10. 10

    Too much of a good thing: a review of primary immune regulatory disorders.

    Tsilifis C, Slatter MA, Gennery AR

    Frontiers in immunology 2023; (14()):1279201 doi:10.3389/fimmu.2023.1279201.

    PMID: 38022498
  11. 11

    Innovations in the care of childhood interstitial lung disease associated with connective tissue disease and immune-mediated disorders.

    Samad A, Wobma H, Casey A

    Pediatric pulmonology 2024; (59(9)):2321-2337 doi:10.1002/ppul.27068.

    PMID: 38837875
  12. 12

    International multidisciplinary consensus on the definition and clinical approach for monogenic inflammatory immune dysregulation disorders.

    Alkwai HM, Almaghlouth IA, Mendonça LO, et al.

    Pediatric rheumatology online journal 2025; (23(1)):51 doi:10.1186/s12969-025-01109-z.

    PMID: 40369629
  13. 13

    Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey.

    Chan AY, Leiding JW, Liu X, et al.

    Frontiers in immunology 2020; (11()):239 doi:10.3389/fimmu.2020.00239.

    PMID: 32153572
  14. 14

    Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood.

    Day JW, Elfeky R, Nicholson B, et al.

    Journal of clinical immunology 2022; (42(6)):1230-1243 doi:10.1007/s10875-022-01278-6.

    PMID: 35579633
  15. 15

    Hematopoietic stem cell transplantation for primary immunodeficiency.

    Alsaati N, Grier A, Ochfeld E, et al.

    Allergy and asthma proceedings 2024; (45(5)):371-383 doi:10.2500/aap.2024.45.240069.

    PMID: 39294909

This page is for informational purposes only and does not constitute medical advice. A pediatric immunologist and the child’s specialist team can help your family choose a care center and plan for ITCH deficiency.